Tissue Core Tissue Microarray Inventory List
|
|
|
- Amie Baldwin
- 5 years ago
- Views:
Transcription
1 size/mm Array description Tissue type # of cases AQUA 1 Pancreas AQUA 1 Pancreas 10 / Pancreas IDC, Panin, IPMN, normal & cysts various types Pancreas Dr. Malafa / Dr. Centeno Exclusive B ALL TMA B ALL 1 / ALL in clot & BM biopsy B.M Dr. Ling Zhang General purpose B Map-3 Her 2-8 / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven B Map-3 Her / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven B Map-3 TN-1 7 / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven B Map-3 TN-2 7 / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven B Map-3 TN-3 8 / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven B Map-3 PRBBBR Her 2-11 / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven B Map-3 PRBBBR Her / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven B Map-3 PRBBBR TN 11 / IDC, cell line (4 types) and Ctr.tissues (5) Breast Dr. Teresita Antonia PI Driven BE-P BE-P 10 / Normal, B.E., HGD, LGD, ICA, Mets. & controls & Stomach Dr. Coppola General Purpose Breast 3 2 / Micropapillary ca.& IDC Breast Dr. Acs General Purpose Breast / Normal, hyperplasia, carcinoma & cell lines Breast Dr.Yeatman / Dr.Coppola General Purpose Breast 2 b 4 / Normal, DCIS, IDC, L.N. macromet. & cell lines Breast Dr. Wu Jerry General Purpose Breast Ca. 4 4 / Normal,DCIS, IDC,L.N.macromet.& cell lines Breast Tissue General Purpose Breast 5 9 / TN BC,ER PR+ BC,N.breast,cell lines & controls Breast Dr. Lancaster / Dr. Marchion PI driven Cervix 1 6 / Cervix 2 5 / Cervix 3 8 / Cervix 4 2 / line Cervix Dr. Siegel / Dr. Hakam PI Driven line Cervix Dr. Siegel / Dr. Hakam PI Driven line Cervix Dr. Siegel / Dr. Hakam PI Driven line Cervix Dr. Siegel / Dr. Hakam PI Driven cmet Development cmet Development 4 / Lung adenoca. ca. + different controls Lung Dr. Haura / Matt Smith PI Driven
2 size/mm Array description Tissue type # of cases Colon 2 A 9 / Normal, adenoma, adenoca.,cell lines and controls Colon different 258 Dr. Shibata Exclusive Colon 2 B 9 / Normal, adenoma, adenoca.,cell lines and controls Colon different 258 Dr. Shibata Exclusive Colon 2 C 10 / Normal, adenoma, adenoca.,cell lines and controls Colon different 258 Dr. Shibata Exclusive Colon 2 D 10 / Normal, adenoma, adenoca.,cell lines and controls Colon different 258 Dr. Shibata Exclusive Colon Control 1 Colon Control 1 1 / Colon ca. and N. Colon Colon Dr. Magliocco PI Driven CRC TMA 1 12 / Cell lines Cell Lines Dr. Haura PI Driven Esophago gastric adenoca. EGA ca. 11 / Gastric, esophageal & GE junction adenoca., low stage & high stage + Ctr. IDC breast & Stomach Dr. Coppola PI Driven Extrahepatic Biliary duct TMA Extrahepatic BDT 5/21/ Extrahepatic biliary duct tumors+normal mucosa+controls (IDC breast her 2 +) Bile Duct Dr.Coppola PI Driven Gastro-esophageal tumor 1,2,3 3 / Adenoca. of the esophagus & stomach & Stomach Merck-Moffitt project General Purpose GIST 1 3 / GIST Many Dr. Pledger / Dr. Coppola General Purpose Glioma 1 9 / Glioma (different grades) and controls Brain Dr. Egan / Dr. Shan Exclusive Glioma 2 10 / Glioma (different grades) and controls Brain Dr. Egan / Dr. Shan Exclusive Glioma 3 12 / Glioma (different grades) and controls Brain Dr. Egan / Dr. Shan Exclusive Glioma 4 2 / Glioma (different grades) and controls Brain Dr. Egan / Dr. Shan Exclusive GVHD 1 6 / GI biopsies (different areas) mostly No GVHD GI Dr.Coppola / Dr. Sagatys General Purpose GVHD 2 7 / GI biopsies (different areas) mostly No GVHD GI Dr.Coppola / Dr. Sagatys General Purpose GVHD 3 11 / GI, skin & liver biopsies Many Dr. Pidala / Dr. Sagatys General Purpose GVHD 4 2 / GI & skin biopsies Many Dr. Pidala / Dr. Sagatys General Purpose GVHD 5 1 / GI & skin biopsies Many Dr. Pidala / Dr. Sagatys PI Driven HCC 1,2,3 5 / Hepatocellular ca. Liver Merck-Moffitt project General Purpose Lung 2 3 / Lung ca. / primary & mets. adenoca.and controls Many Dr. Haura / Dr. Khalil Exclusive
3 size/mm Array description Tissue type # of cases Lung 1 3 / Lung ca. / primary & mets.adenoca. and controls Many Dr. Haura / Dr. Khalil Exclusive Lung 3 6 / Lung ca. / primary & mets. adenoca. and controls Many Dr. Haura / Dr.Khalil Exclusive Lung 4 6 / Lung ca.(adenoca.,sq.cc,nscc,), mets., normal and controls Many Dr. Haura / Dr. Magliocco Exclusive Lung 5 (KRAS) 1 / Lung ca., normal lung tissue, controls and cell line Lung Dr. Haura Exclusive Lung 6 (ALK) 2 / Lung ca., controls and cell line Lung Dr. Haura Exclusive Lung 6-2 ALK Lung / Lung ca., cell line and controls Lung Dr. Haura PI driven Lung 7 4 / Lung ca. - primary & mets, different controls Lung & Many Dr. Robinson PI Driven Lung Control 1 Lung Control 1 1 / Lung ca. Lung Dr. Magliocco PI Driven Lung Small cell ca. Lung Small cell ca. 4 / Lung small cell ca., controls & cell line Lung Dr. Scott Antonia PI driven Lymphoma 1 3 / Hodgkin's lymphoma, Diffuse large B cell lymphoma & controls L.N Dr. Haipeng Shao General Purpose Melanoma 1 10 / Melanoma 2 1 / Normal, benign nevi, dysplastic nevi, Primary cutan.melanoma, M1,2,3, regional L.N. melanoma & primary mucosal melanoma Skin Dr. Sondak / Dr. Messina General Purpose Primary cutan. melanoma, subcutaneous melanoma, L.N.melanoma mets. & distant mets. Melanoma Skin Dr. Sondak / Dr. Messina Exclusive Melanoma stage 3&4 3 2 / Melanoma stage 3 &4 and controls Many Dr. Gibney / Dr. Messina PI driven Melanoma stage 3&4 4 2 / Melanoma stage 3 &4 and controls Many Dr. Gibney / Dr. Messina General purpose Melanoma 5 10 / Desmoplastic Melanoma Many Dr. Messina PI Driven Merkel cell Ca. Merkel cell Ca. 7 / Diff. tissues Primary lesion, L.N. involv. & recurrent/mets. cases Many Dr.Messina PI Driven Met Cells Met Cells TMA 3 / cell lines + controls Cell Lines Dr. Haura / Matt Smith PI Driven Mini Bladder 1 MRE11 Mini Bladder 1 MRE11 7 / Bladder ca., normal urothelial tissue & cell line Bladder Dr. Magliocco PI Driven Mini Myeloma 2 2 / Multiple myeloma and controls B.M Dr. Hazlehurst / Dr. Zhang General Purpose Mini Myeloma 10 / Multiple myeloma and controls B.M Dr. Hazlehurst / Dr. Zhang General Purpose Mini P BAD ov.ca 1 5 / / ovarian ca., normal ovary, normal fallopian tube, cell line and controls (normal kidney& breast ca.) Ovary & F.T Dr. Lancaster / Dr. Magliocco PI Driven
4 size/mm Array description Tissue type # of cases MM / MM cases, normal BM & cell line B.M Dr. Hazlehurst / Dr. Zhang PI Driven Mouse EM Mouse EM TMA 3 / Mouse uterus endometriosis, ovary, different controls Uterus & Ovary Meera / USF PI Driven Next Gen OVCA 1 2 / 2015 ovary cancer, normal ovary, N.FT, different controls & cell lines Ovary Dr. Wey PI Driven Next Gen OVCA 2 2 / 2015 ovary cancer, normal ovary, N.FT, different controls & cell lines Ovary Dr. Wey PI Driven Next Gen OVCA 3 2 / 2015 ovary cancer, normal ovary, N.FT, different controls & cell lines Ovary Dr. Wey PI Driven Next Gen OVCA 4 2 / 2015 ovary cancer, normal ovary, N.FT, different controls & cell lines Ovary Dr. Wey PI Driven Next Gen OVCA 5 2 / 2015 ovary cancer, normal ovary, N.FT, different controls & cell lines Ovary Dr. Wey PI Driven Osteosarcoma 3 3 / Osteosarcoma in different sites, mets. and controls Many Dr. Bui Exclusive Osteosarcoma 4 3 / Osteosarcoma in different sites, mets. and controls Many Dr. Bui Exclusive Ovarian tumor 1 8 / different types of ovarian tumor Ovary Dr. Tuya Pal / Dr. Coppola General Purpose P BAD ov.ca / ovarian ca., normal ovary, normal fallopian tube, cell line and controls (normal kidney& breast ca.) Ovary & F.T Dr. Lancaster / Dr. Magliocco General Purpose Pancreas 1 1 / Normal, IDC & cell lines Pancreas Dr. Malafa / Dr. Centeno General Purpose Pancreas 2 3 / Normal, IDC & cell lines Pancreas Dr. Malafa / Dr. Centeno General Purpose Pancreas 3 9 / Normal, IDC & cell lines Pancreas Dr. Malafa / Dr. Centeno General Purpose Pancreas 4 9 / Neuroendocrine ca.(well-mod.diff.) Pancreas Dr. Nasir General Purpose Pancreas 5 9 / Neuroendocrine ca. Pancreas Dr. Nasir General Purpose Pancreas 6 A 8/6/ Normal,IDC, cell lines & Ctr. Tissue tissue Dr. Malafa PI driven Pancreas 6 B 8/13/ Normal,IDC, cell lines & Ctr. Tissue tissue Dr. Malafa PI driven Pancreas 6 C 8/26/ Normal,IDC, cell lines & Ctr. Tissue tissue Dr. Malafa PI driven Control 1 Control 1 1 / ca., N. Pancreas & N. Duodenum Pancreas Dr. Magliocco PI Driven tumor 11,12,13 4 / Adenoca. of the pancreas Pancreas Merck-Moffitt project General Purpose Penile ca. TMA Penile ca. 6/16/ Penile SCC+ controls Penis Dr. Dhillon PI driven PR BB Colon / Colon ca., HGD, Adenoma, N. colon, cell line & controls Colon Dr. Munoz-Antonia PI driven
5 size/mm Array description Tissue type # of cases PR BB Colon / Colon ca., HGD, Adenoma, N. colon, cell line & controls Colon Dr. Munoz-Antonia PI driven PR BB Colon / Colon ca., HGD, Adenoma, N. colon, cell line & controls Colon Dr. Munoz-Antonia PI driven Prostate 3 1 / BPH, PIN, G6, G7, G8-9-10, mets. & cell lines Prostate Dr. Mahajan General Purpose
Epidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
Supplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
National Cancer Statistics in Korea, 2014
National Cancer Statistics in Korea, 2014 2016. 12. 20. Korea Central Cancer Registry Cancer Incidence in Korea, 2014 National Cancer Incidence, 2014 Trends in Cancer Incidence by Sex and Year * Dark colored
Radiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
MT09 - Normal Human Tissue Microarray, FDA
Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA MT09 - Normal Human Tissue Microarray,
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
The clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
Cancer prevalence. Chapter 7
Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.
Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption
Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption X Dong, Y Ren, R Wilson, and K Zhang NAACCR 6-20-2017 Introduction
Cancer in New Mexico 2017
Cancer in New Mexico 0 Please contact us! Phone: 0-- E-Mail: nmtr-info@salud.unm.edu URL: nmtrweb.unm.edu TABLE OF CONTENTS Introduction... New Cases of Cancer Estimated Number of New Cancer Cases Description
Cancer in Ontario. 1 in 2. Ontarians will develop cancer in their lifetime. 1 in 4. Ontarians will die from cancer
Cancer in Ontario 1 in 2 Ontarians will develop cancer in their lifetime 1 in 4 Ontarians will die from cancer 14 ONTARIO CANCER STATISTICS 2016 1 Cancer in Ontario An overview Cancer is a group of more
Cancer in New Mexico 2014
Cancer in New Mexico 2014 Please contact us! Phone: 505-272-5541 E-Mail: info@nmtr.unm.edu http://som.unm.edu/nmtr/ TABLE OF CONTENTS Introduction... 1 New Cases of Cancer: Estimated Number of New Cancer
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013 All ages Younger than 45 45 and Older Younger than 65 65 and Older All sites, men 306,920 9,370 297,550 95,980 210,940 All sites,
Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials
Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials Mary Beth Terry, PhD Department of Epidemiology Mailman School of Public Health Racial and Ethnic Disparities in
2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
APPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
Tumor Markers & Cytopathology
Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)
Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.
Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer
Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004
MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer
Supporting Information
Supporting Information Vaira et al. 10.1073/pnas.0907676107 0h 24h 48h PTEN pathway Expression 0h 24h 48h Time MAP Kinase Signaling Pathway Expression 0h 24h 48h Time Collagen Expression Fig. S1. Differential
Cancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
Checklist; Anus: Excisional Biopsy Anus: Excisional Biopsy 1/1/ Checklist; Anus: Resection Anus: Resection 1/1/2005
ChecklistTemplateVersions ChecklistTemplateVersion Ckey OfficialName VisibleText RevisionDate Checklist; Adrenal gland: 16.1000043 Resection Adrenal gland: Checklist; Ampulla of 17.1000043 Vater: Ampullectomy
ANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
Differential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
Version 2 Overview and Update CSv0202 to CSv0203
Version 2 Overview and Update CSv0202 to CSv0203 CS version 2 Education and Training Team What We ll Cover Rules changes and revisions CSv0202 to CSv0203 Sites with Major Changes Esophagus and Stomach
Comprehensive Cancer Cover
Comprehensive Cancer Cover Tech Spec Comprehensive Cancer Cover provides the life insured with cover for the diagnosis and treatment of defined malignant tumours. These tumours must be characterised either
Burden of Cancer in California
Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality
Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director
Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer
Comprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
Information Services Division NHS National Services Scotland
Cancer in Scotland April 2017 First published in June 2004, revised with each National Statistics publication Next due for revision October 2017 Information Services Division NHS National Services Scotland
America, Hershey, PA Australia, Melbourne, VIC Europe, Munich
America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Bladder MB-9-luc 2 Mouse urinary bladder carcinoma yes yes yes C57BL/6 2 Bone UMR-106 Rat osteosarcoma
SHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
GASTROINTESTINAL IMAGING STUDY GUIDE
GASTROINTESTINAL IMAGING STUDY GUIDE Pharynx Diverticula Foreign bodies Trauma o Motility Disorders Esophagus Diverticula Trauma Esophagitis Barrett esophagus Rings, webs, and strictures Varices Benign
Comprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
Cancer in Utah: An Overview of Cancer Incidence and Mortality from
Cancer in Utah: An Overview of Cancer Incidence and Mortality from 1973-2010 A publication of the Utah Cancer Registry January 2014 Prepared by: C. Janna Harrell, MS Senior Research Analyst Kimberly A.
Supplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
Learning Outcomes: The following list provides the learning objectives that will be covered in the lectures, and tutorials of each week:
Course Code Course Title ECTS Credits MED-309 Pathology II 6 School Semester Prerequisites Medical School Spring (Semester 6) MED-304 Pathology I Type of Course Field Language of Instruction Required Medicine
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator December 2014 334 Jefferson Avenue, Scranton,
Multi-normal human tissues, FDA, 96 samples, 35 organs/sites from three individuals (1.5mm)
ab178228 Multi-normal human tissues, FDA, 96 samples, 35 organs/sites from three individuals (1.5mm) Instructions for Use Designed for antibody cross reactivity analysis and IHC or ISH based protein or
Duodenal adenomas Management. Dr Stratis Alexandridis Consultant Gastroenterologist BRI
Duodenal adenomas Management Dr Stratis Alexandridis Consultant Gastroenterologist BRI Introduction Ampullary and non ampullary polyps of the duodenum are diagnosed within and outside genetic syndromes.
Information Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator November 2018 334 Jefferson Avenue, Scranton,
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator December 2017 334 Jefferson Avenue, Scranton,
ACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
Samuel M. Lesko, MD, MPH Director of Research/Medical Director
Cancer in Northeastern Pennsylvania: Incidence, Mortality and Survival for Common Cancers Samuel M. Lesko, MD, MPH Director of Research/Medical Director May 11 334 Jefferson Avenue, Scranton, PA 1851-57-941-7984
Information Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
Diagnostic IHC in lung and pleura pathology
Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid
Smoking and Mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC)
Smoking and Mortality SECTION 6 Smoking and Mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC) Kotaro Ozasa Abstract In the JACC study, risk of death with all cancers and
Bioengineering and World Health. Lecture Twelve
Bioengineering and World Health Lecture Twelve Four Questions What are the major health problems worldwide? Who pays to solve problems in health care? How can technology solve health care problems? How
*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
Case 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow
Case 3 - GYN History: 66 year old, routine Pap test Dr. Stelow Case 3 66 year year old woman Routine Pap Test Cytologic Features 3 dimensional clusters of cells with small to moderate amount of
Cancer A Superficial Introduction
Cancer A Superficial Introduction Gabor Fichtinger, Queen s University Cancer some definitions Medical term: malignant neoplasm Class of diseases in which a group of cells display: uncontrolled growth
Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths
RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected
For more information about how to cite these materials visit
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Non-commercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
ALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2012-2016) AVERAGE NUMBER OF DEATHS PER YEAR (2012-2016) Male Female Both sexes Male Female Both sexes 4,607 4,632 9,240 1 2,238 2,036 4,274
Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
Cancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on ICD-10 Coding of Neoplasms Introduction The International Statistical Classification of Diseases and Related Health Problems, 10 th Revision (ICD-10)
Cancer in Colorado Incidence, Mortality, and Survival
Cancer in Colorado 1998-2003 Incidence, Mortality, and Survival Jack L. Finch, M.S. Statistical Analyst III Kieu O. Vu, M.S.P.H. Statistical Analyst II 2007 Colorado Central Cancer Registry Randi K. Rycroft,
Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts
Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts Chris Johnson, Cancer Data Registry of Idaho NAACCR 2016 Annual Conference June 14, 2016 Concurrent
CEA (CARCINOEMBRYONIC ANTIGEN)
(CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant
Development status of OPDIVO (nivolumab) 1
August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung
MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Radiology Pathology Conference
Radiology Pathology Conference Nadia F. Yusaf, M.D. PGY-3 1/29/2010 Presentation material is for education purposes only. All rights reserved. 2010 URMC Radiology Page 1 of 90 Case 1 60 year- old man presents
PET/CT F-18 FDG. Objectives. Basics of PET/CT Imaging. Objectives. Basic PET imaging
Basics of PET/CT Imaging Kevin Robinson, DO Department of Radiology Michigan State University Objectives Basic PET imaging Evaluating the therapeutic response Evaluating the big 5 Lymphoma Breast Lung
Annual Report to the Nation on the Status of Cancer, , Featuring Survival Questions and Answers
EMBARGOED FOR RELEASE CONTACT: Friday, March 31, 2017 NCI Media Relations Branch: (301) 496-6641 or 10:00 am EDT ncipressofficers@mail.nih.gov NAACCR: (217) 698-0800 or bkohler@naaccr.org ACS Press Office:
Oncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
Urinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
The role of appropriateness criteria in the planning of health services: the case of FDG-PET in oncology
V Annual Meeting of Health Tecnology Assessment International (HTAi) MONTREAL 8 july 2008 The role of appropriateness criteria in the planning of health services: the case of FDG-PET in oncology L. BALLINI
Valida5on of a Microsatellite Instability Assay by NGS
Valida5on of a Microsatellite Instability Assay by NGS Mark R. Miglarese, Ph.D. VP R&D 1 Caris Life Sciences 230,000+ tests performed in 2016 Headquarters: Irving, Texas Laboratory: Phoenix, Arizona 66,000
Video Microscopy Tutorial 8
Video Microscopy Tutorial 8 Common and Uncommon Lesions of the Liver Gladwyn Leiman, MD There are no disclosures necessary. Common and Uncommon Lesions in Liver FNA Gladwyn Leiman University of Vermont
CANCER FACTS & FIGURES For African Americans
CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5
Early Cancer Care FAQ
If you need more information, you can call 6722 2293 (Mon-Fri, 9am-5pm), email our Financial Protection Specialists at financial2@ocbc.com or visit any of our OCBC branches. Q1. What is this Early Cancer
Trends and disparities in cancer in Aotearoa/ NZ
Trends and disparities in cancer in Aotearoa/ NZ Professor Diana Sarfati #cancercrossroads @DiSarfati Why cancer? Estimated number of incident cases from 2018 to 2040 in New Zealand, all cancers, both
Cancer in Rural Illinois, Incidence, Mortality, Staging, and Access to Care. April 2014
Cancer in Rural Illinois, 1990-2010 Incidence, Mortality, Staging, and Access to Care April 2014 Prepared by Whitney E. Zahnd, MS Research Development Coordinator Center for Clinical Research Southern
Cancer in Maine: Using Data to Direct Actions 2018 Challenge Cancer Conference May 1, 2018
Cancer in Maine: Using Data to Direct Actions 2018 Challenge Cancer Conference May 1, 2018 Tim Cowan, MSPH Director, Data Reporting and Evaluation Center for Health Improvement MaineHealth All Cancer Mortality
Cancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
Detection: Rabab Gaafar,MD. Prof. Medical Oncology NCI,Cairo, Cairo University
Cancer Prevention and Early Detection: Rabab Gaafar,MD Prof. Medical Oncology NCI,Cairo, Cairo University Director Early Detection Unit Prevention and Early Detection Definition Goals of Cancer Prevention
NIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2005 December 15; 104(12 Suppl): 2989 2998. 1999 2001 Cancer Mortality Rates for Asian and Pacific Islander Ethnic Groups
ProteoScan Cancer Lysate Arrays. QC and Validation Data
ProteoScan Cancer Lysate Arrays QC and Validation Data 4.5 mm Barcode Cancer Lysate Array Layout PA02 60 mm B1 C2 K3 Ly1 O2 P3 Mel1 Lv2 St3 B2 C3 L1 Ly2 O3 Pr1 Mel2 Lv3 B3 K1 L2 Ly3 P1 Pr2 Mel3 St1 C1
Exploring the healthcare cost implications of cancer stage. England level modelling
Exploring the healthcare cost implications of cancer stage England level modelling Rachel White (Rwhite@macmillan.org.uk) Thursday 22 nd September 2016 What we re covering Modelling methods Results - variation
Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring
Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays Excellent precision Confident cancer monitoring Thermo Scientific B R A H M S Biomarkers Tumor Markers Parameter Clinical Interest Product Technology
Annual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.
Annual Report Cape Cod Hospital and Falmouth Hospital Regional Cancer Network 2013 Expert physicians. Quality hospitals. Superior care. Cape Cod Hospital s Davenport- Mugar Hematology/Oncology Center and
Development status of OPDIVO (nivolumab) 1
November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell
Development Pipeline Progress Status. February 1, 2019
Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
Surgical Treatment of special Tumours. Winnie Achilles Tierklinik Hollabrunn Lastenstrasse Hollabrunn
Surgical Treatment of special Tumours Winnie Achilles Tierklinik Hollabrunn Lastenstrasse 2 2020 Hollabrunn boexi@gmx.de Hepatocellular Tumours Hepatocellular Carcinoma, hepatocellular adenoma, and hepatoblastoma
The Cancer Burden in California. Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012
The Cancer Burden in California Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012 Goals Introduce you to the California Cancer Registry (CCR) Provide an
Thymidine Kinase 1: A Universal Marker for Cancer
Cancer and Clinical Oncology; Vol. 2, No. 1; 2013 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Thymidine Kinase 1: A Universal Marker for Cancer Melissa M. Alegre
ICD-O-3 UPDATES - PENDING
ICD-O-3 UPDATES - PENDING FCDS Annual Meeting July 26, 2013 Sunrise, Florida Steven Peace, CTR ICD-O-3 Work Group ICD-O-3 WORK GROUP Name April Fritz, CTR Lynn Ries, MS Lois Dickie, CTR Linda Mulvihill,